Sasirekha Ramani1, Robert L Atmar, Mary K Estes. 1. aDepartment of Molecular Virology and Microbiology bDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: Noroviruses (NoVs) are the most common cause of epidemic and sporadic cases of acute gastroenteritis worldwide. This review summarizes recent NoV disease burden estimates, epidemiology findings and provides an update on virus-like particle (VLP) vaccine studies. RECENT FINDINGS: NoVs are the leading cause of food-borne gastroenteritis and are replacing rotavirus as the predominant gastrointestinal pathogen in pediatric populations. Genogroup II, genotype 4 NoVs (GII.4) remain the dominant genotype worldwide. Increased NoV activity reported in late 2012 was associated with the emergence of a new GII.4 variant called Sydney 2012. New studies suggest that human NoVs can bind a larger range of histoblood group antigens, a susceptibility factor for NoV illness, thus expanding the susceptible population pool for infection. Intranasal immunization with a monovalent GI NoV VLP vaccine showed proof-of-concept efficacy. Studies using intramuscular immunization with a bivalent formulation including GII.4 VLPs are now underway. SUMMARY: The importance of NoVs as a major gastrointestinal pathogen underscores the need for well tolerated and effective vaccines. Results of VLP vaccine trials appear promising. However, the rapid evolution of NoV genotypes through antigenic drift and changing glycan specificities provide new challenges to epidemiology studies and vaccine trials.
PURPOSE OF REVIEW: Noroviruses (NoVs) are the most common cause of epidemic and sporadic cases of acute gastroenteritis worldwide. This review summarizes recent NoV disease burden estimates, epidemiology findings and provides an update on virus-like particle (VLP) vaccine studies. RECENT FINDINGS: NoVs are the leading cause of food-borne gastroenteritis and are replacing rotavirus as the predominant gastrointestinal pathogen in pediatric populations. Genogroup II, genotype 4 NoVs (GII.4) remain the dominant genotype worldwide. Increased NoV activity reported in late 2012 was associated with the emergence of a new GII.4 variant called Sydney 2012. New studies suggest that human NoVs can bind a larger range of histoblood group antigens, a susceptibility factor for NoV illness, thus expanding the susceptible population pool for infection. Intranasal immunization with a monovalent GI NoVVLP vaccine showed proof-of-concept efficacy. Studies using intramuscular immunization with a bivalent formulation including GII.4 VLPs are now underway. SUMMARY: The importance of NoVs as a major gastrointestinal pathogen underscores the need for well tolerated and effective vaccines. Results of VLP vaccine trials appear promising. However, the rapid evolution of NoV genotypes through antigenic drift and changing glycan specificities provide new challenges to epidemiology studies and vaccine trials.
Authors: Rishi Desai; Christal D Hembree; Andreas Handel; Jonathan E Matthews; Benjamin W Dickey; Sharla McDonald; Aron J Hall; Umesh D Parashar; Juan S Leon; Benjamin Lopman Journal: Clin Infect Dis Date: 2012-04-04 Impact factor: 9.079
Authors: Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: J E Matthews; B W Dickey; R D Miller; J R Felzer; B P Dawson; A S Lee; J J Rocks; J Kiel; J S Montes; C L Moe; J N S Eisenberg; J S Leon Journal: Epidemiol Infect Date: 2012-03-26 Impact factor: 2.451
Authors: Amanda Reeck; Owen Kavanagh; Mary K Estes; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Gabriel I Parra; Karin Bok; Ross Taylor; Joel R Haynes; Stanislav V Sosnovtsev; Charles Richardson; Kim Y Green Journal: Vaccine Date: 2012-03-31 Impact factor: 3.641
Authors: Annelies Kroneman; Everardo Vega; Harry Vennema; Jan Vinjé; Peter A White; Grant Hansman; Kim Green; Vito Martella; Kazuhiko Katayama; Marion Koopmans Journal: Arch Virol Date: 2013-04-25 Impact factor: 2.574
Authors: Kirsten Mattison; Anu Shukla; Angela Cook; Frank Pollari; Robert Friendship; David Kelton; Sabah Bidawid; Jeffrey M Farber Journal: Emerg Infect Dis Date: 2007-08 Impact factor: 6.883
Authors: Stefan Taube; Abimbola O Kolawole; Marina Höhne; John E Wilkinson; Scott A Handley; Jeffrey W Perry; Larissa B Thackray; Ramesh Akkina; Christiane E Wobus Journal: MBio Date: 2013-07-16 Impact factor: 7.867
Authors: Baijun Kou; Wanzhi Huang; Frederick H Neill; Timothy Palzkill; Mary K Estes; Robert L Atmar Journal: J Clin Microbiol Date: 2015-10-07 Impact factor: 5.948
Authors: Shayla Hesse; Frederick H Neill; Mary K Estes; Sreejesh Shanker; B V Venkataram Prasad; Jennifer Ferreira; Robert L Atmar Journal: Clin Vaccine Immunol Date: 2015-12-09
Authors: Mariya A Viskovska; Boyang Zhao; Sreejesh Shanker; Jae-Mun Choi; Lisheng Deng; Yongchen Song; Timothy Palzkill; Liya Hu; Mary K Estes; B V Venkataram Prasad Journal: J Virol Date: 2019-03-05 Impact factor: 5.103
Authors: Robert L Atmar; David I Bernstein; G Marshall Lyon; John J Treanor; Mohamed S Al-Ibrahim; David Y Graham; Jan Vinjé; Xi Jiang; Nicole Gregoricus; Robert W Frenck; Christine L Moe; Wilbur H Chen; Jennifer Ferreira; Jill Barrett; Antone R Opekun; Mary K Estes; Astrid Borkowski; Frank Baehner; Robert Goodwin; Anthony Edmonds; Paul M Mendelman Journal: Clin Vaccine Immunol Date: 2015-06-03
Authors: Baijun Kou; Sue E Crawford; Nadim J Ajami; Rita Czakó; Frederick H Neill; Tomoyuki N Tanaka; Noritoshi Kitamoto; Timothy G Palzkill; Mary K Estes; Robert L Atmar Journal: Clin Vaccine Immunol Date: 2014-11-26
Authors: Anushka C Galasiti Kankanamalage; Yunjeong Kim; Pathum M Weerawarna; Roxanne Adeline Z Uy; Vishnu C Damalanka; Sivakoteswara Rao Mandadapu; Kevin R Alliston; Nurjahan Mehzabeen; Kevin P Battaile; Scott Lovell; Kyeong-Ok Chang; William C Groutas Journal: J Med Chem Date: 2015-03-19 Impact factor: 7.446
Authors: Khalil Ettayebi; Sue E Crawford; Kosuke Murakami; James R Broughman; Umesh Karandikar; Victoria R Tenge; Frederick H Neill; Sarah E Blutt; Xi-Lei Zeng; Lin Qu; Baijun Kou; Antone R Opekun; Douglas Burrin; David Y Graham; Sasirekha Ramani; Robert L Atmar; Mary K Estes Journal: Science Date: 2016-08-25 Impact factor: 47.728